{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.22","value":"99.93"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Mean myeloid chimerism expressed as a percentage of donor cells","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSCT\n\nTotal-Body Irradiation: Undergo TBI","id":"OG000","title":"Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)"}],"paramType":"MEAN","populationDescription":"All treated and eligible patients. Samples were not obtained at day 100 for 8 subjects.","reportingStatus":"POSTED","timeFrame":"At 100 days","title":"Myeloid Chimerism Expressed as a Percentage of Donor Cells","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of donor cells"}